Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON regimen with biweekly cetuximab plus encorafenib in pre-treated BRAFV600E metastatic colorectal cancer
2020-003283-10Phase 2Active
- Sponsor
- Camilla Qvortrup
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib and cetuximab in colorectal adenocarcinoma, sponsored by Camilla Qvortrup. Primary endpoint: 2-month progression-free survival rate. Started Sep 2020; status: active.
02
Drugs
encorafenibcetuximab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2020-003283-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003283-10.